Cargando…

Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines

Hydrazine is an alkaline reduction compound which is widely used in synthesis. Based on the structure–activity analysis, to elicit antitumor activity, the presence of the N-methyl group is an absolute requirement. The aim of the research is to synthesize a new hydrazine derivate compound that has po...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasetiawati, Riska, Hidayat, Syahrul, Zamri, Adel, Muchtaridi, Muchtaridi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784035/
https://www.ncbi.nlm.nih.gov/pubmed/36568052
http://dx.doi.org/10.4103/japtr.japtr_435_22
_version_ 1784857714898239488
author Prasetiawati, Riska
Hidayat, Syahrul
Zamri, Adel
Muchtaridi, Muchtaridi
author_facet Prasetiawati, Riska
Hidayat, Syahrul
Zamri, Adel
Muchtaridi, Muchtaridi
author_sort Prasetiawati, Riska
collection PubMed
description Hydrazine is an alkaline reduction compound which is widely used in synthesis. Based on the structure–activity analysis, to elicit antitumor activity, the presence of the N-methyl group is an absolute requirement. The aim of the research is to synthesize a new hydrazine derivate compound that has potency as a novel anti-breast cancer. 4-hydrazinylphenyl benzenesulfonate was synthesized employing reduction and diazotization methods. Structure characterization was carried out using Fourier transform infrared (FTIR), C13-nuclear magnetic resonance (NMR), H1-NMR, and High Resolution Time-of-Flight Mass Spectrometry (HR-TOF-MS). The anti-cancer activity of this compound against breast cancer Michigan Cancer Foundation-7 (MCF-7) cell line was determined using a PrestoBlue viability assay. The new of hydrazine derivative, 4-hydrazinylphenyl benzenesulfonate, has been successfully synthesized. The reduction and diazotization methods have been successfully used in the synthesis of new compound of hydrazine derivatives. Structure characterization of 4-hydrazinylphenyl benzenesulfonate was established using FTIR, C13-NMR, H1-NMR, and HR-TOF-MS. The anti-cancer activity of this compound against breast cancer MCF-7 cell line was determined using a PrestoBlue viability assay with IC50 0.00246 μg/mL or 9.32 nM. In conclusion, 4-hydrazinylphenyl benzenesulfonate was successfully synthesized as a new candidate for anti-breast cancer compound.
format Online
Article
Text
id pubmed-9784035
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-97840352022-12-24 Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines Prasetiawati, Riska Hidayat, Syahrul Zamri, Adel Muchtaridi, Muchtaridi J Adv Pharm Technol Res Original Article Hydrazine is an alkaline reduction compound which is widely used in synthesis. Based on the structure–activity analysis, to elicit antitumor activity, the presence of the N-methyl group is an absolute requirement. The aim of the research is to synthesize a new hydrazine derivate compound that has potency as a novel anti-breast cancer. 4-hydrazinylphenyl benzenesulfonate was synthesized employing reduction and diazotization methods. Structure characterization was carried out using Fourier transform infrared (FTIR), C13-nuclear magnetic resonance (NMR), H1-NMR, and High Resolution Time-of-Flight Mass Spectrometry (HR-TOF-MS). The anti-cancer activity of this compound against breast cancer Michigan Cancer Foundation-7 (MCF-7) cell line was determined using a PrestoBlue viability assay. The new of hydrazine derivative, 4-hydrazinylphenyl benzenesulfonate, has been successfully synthesized. The reduction and diazotization methods have been successfully used in the synthesis of new compound of hydrazine derivatives. Structure characterization of 4-hydrazinylphenyl benzenesulfonate was established using FTIR, C13-NMR, H1-NMR, and HR-TOF-MS. The anti-cancer activity of this compound against breast cancer MCF-7 cell line was determined using a PrestoBlue viability assay with IC50 0.00246 μg/mL or 9.32 nM. In conclusion, 4-hydrazinylphenyl benzenesulfonate was successfully synthesized as a new candidate for anti-breast cancer compound. Wolters Kluwer - Medknow 2022 2022-10-10 /pmc/articles/PMC9784035/ /pubmed/36568052 http://dx.doi.org/10.4103/japtr.japtr_435_22 Text en Copyright: © 2022 Journal of Advanced Pharmaceutical Technology & Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Prasetiawati, Riska
Hidayat, Syahrul
Zamri, Adel
Muchtaridi, Muchtaridi
Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines
title Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines
title_full Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines
title_fullStr Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines
title_full_unstemmed Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines
title_short Nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer Michigan Cancer Foundation-7 cell lines
title_sort nanomolar activity of 4-hydrazinylphenyl benzenesulfonate against breast cancer michigan cancer foundation-7 cell lines
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784035/
https://www.ncbi.nlm.nih.gov/pubmed/36568052
http://dx.doi.org/10.4103/japtr.japtr_435_22
work_keys_str_mv AT prasetiawatiriska nanomolaractivityof4hydrazinylphenylbenzenesulfonateagainstbreastcancermichigancancerfoundation7celllines
AT hidayatsyahrul nanomolaractivityof4hydrazinylphenylbenzenesulfonateagainstbreastcancermichigancancerfoundation7celllines
AT zamriadel nanomolaractivityof4hydrazinylphenylbenzenesulfonateagainstbreastcancermichigancancerfoundation7celllines
AT muchtaridimuchtaridi nanomolaractivityof4hydrazinylphenylbenzenesulfonateagainstbreastcancermichigancancerfoundation7celllines